Dynavax Technologies Newswire

Dynavax Technologies Newswire

Comprehensive Real-Time News Feed for Dynavax Technologies.

Results 1 - 20 of 264 in Dynavax Technologies

  1. Zacks Investment Research Upgrades Dynavax Technologies Corp. (DVAX) to "Hold"Read the original story w/Photo

    Wednesday | AmericanBankingNews.com

    According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

    Comment?

  2. Dynavax Technologies Corp. (DVAX) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Wednesday | AmericanBankingNews.com

    According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

    Comment?

  3. Dynavax Technologies Corp. (DVAX) Trading Up 2.4%Read the original story w/Photo

    Wednesday | Daily Political

    Dynavax Technologies Corp. was up 2.4% during trading on Wednesday . The stock traded as high as $17.50 and last traded at $17.26, with a volume of 267,115 shares trading hands.

    Comment?

  4. Dynavax Technologies Corp. (DVAX) Trading Up 3.6%Read the original story w/Photo

    Saturday Aug 20 | Daily Political

    Dynavax Technologies Corp. 's share price was up 3.6% during mid-day trading on Thursday . The company traded as high as $16.21 and last traded at $16.20, with a volume of 240,590 shares traded.

    Comment?

  5. Dynavax Technologies Corp. (DVAX) Stock Price Up 3.6%Read the original story w/Photo

    Thursday Aug 18 | Daily Political

    Dynavax Technologies Corp. rose 3.6% during mid-day trading on Thursday . The company traded as high as $16.21 and last traded at $16.20, with a volume of 240,590 shares trading hands.

    Comment?

  6. Dynavax Technologies Corp. (DVAX) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Thursday Aug 18 | Daily Political

    According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

    Comment?

  7. Dynavax Technologies Corp. (DVAX) Sees Strong Trading VolumeRead the original story w/Photo

    Wednesday Aug 17 | Daily Political

    Dynavax Technologies Corp. saw unusually-high trading volume on Wednesday . Approximately 690,835 shares were traded during trading, an increase of 15% from the previous session's volume of 601,301 shares.The stock last traded at $15.65 and had previously closed at $15.94.

    Comment?

  8. Dynavax Technologies Corp. (DVAX) Lowered to Sell at Zacks Investment ResearchRead the original story w/Photo

    Tuesday Aug 16 | AmericanBankingNews.com

    According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

    Comment?

  9. Zacks Investment Research Lowers Dynavax Technologies Corp. (DVAX) to SellRead the original story w/Photo

    Tuesday Aug 16 | AmericanBankingNews.com

    According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

    Comment?

  10. Dynavax Technologies Corp. (DVAX) Sees Strong Trading VolumeRead the original story w/Photo

    Saturday Aug 13 | Daily Political

    Dynavax Technologies Corp. shares saw strong trading volume on Thursday . 1,119,899 shares were traded during trading, an increase of 74% from the previous session's volume of 643,472 shares.The stock last traded at $16.07 and had previously closed at $15.72.

    Comment?

  11. Zacks: Dynavax Technologies Corp. (NASDAQ:DVAX) Given Average Rating of "Buy" by AnalystsRead the original story w/Photo

    Wednesday Aug 10 | Daily Political

    Dynavax Technologies Corp. has earned a consensus broker rating score of 2.00 from the four analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company.

    Comment?

  12. Dynavax Technologies Corp. (DVAX) Cut to Sell at Zacks Investment ResearchRead the original story w/Photo

    Wednesday Aug 10 | AmericanBankingNews.com

    According to Zacks, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

    Comment?

  13. Dynavax Technologies Corp. (DVAX) to Post Q3 2016 Earnings of ($0.74) ...Read the original story w/Photo

    Wednesday Aug 10 | AmericanBankingNews.com

    Dynavax Technologies Corp. - Equities researchers at William Blair reduced their Q3 2016 earnings estimates for shares of Dynavax Technologies Corp. in a research report issued on Monday. William Blair analyst Y. Xu now expects that the brokerage will post earnings per share of for the quarter, down from their previous estimate of .

    Comment?

  14. Dynavax Technologies Corp. (DVAX) Posts Earnings Results, Misses Estimates By $0.07 EPSRead the original story w/Photo

    Tuesday Aug 9 | Daily Political

    Dynavax Technologies Corp. posted its earnings results on Friday. The biopharmaceutical company reported earnings per share for the quarter, missing analysts' consensus estimates of by $0.07.

    Comment?

  15. FDA Advisors Schedule Meeting to Review Hepatitis B VaccineRead the original story

    Monday Aug 8 | P&T Community

    ... review the biologics license application for Heplisav-B (hepatitis B vaccine, recombinant [adjuvanted], Dynavax Technologies Corporation) at a meeting scheduled for November 16. Heplisav-B is a vaccine candidate for immunization against infection ...

    Comment?

  16. Dynavax Technologies Corp. (DVAX) Trading Down 4.9% Following Weak EarningsRead the original story w/Photo

    Monday Aug 8 | Daily Political

    Dynavax Technologies Corp. shares traded down 4.9% during mid-day trading on Monday following a weaker than expected earnings announcement. The company traded as low as $15.10 and last traded at $15.91, with a volume of 1,015,860 shares.

    Comment?

  17. Mid-Day Market Update: Mattress Firm Jumps Following Buyout; Digital Ally Shares SlideRead the original story

    Monday Aug 8 | Benzinga

    ... trading on Monday, healthcare shares fell by 0.88 percent. Meanwhile, top losers in the sector included Dynavax Technologies Corporation (NASDAQ: DVAX ), down 6 percent, and AMN Healthcare Services, Inc. (NYSE: AHS ), down 7 percent. The company ...

    Comment?

  18. Analysts Anticipate Dynavax Technologies Corp. (NASDAQ:DVAX) to Post ($0.68) EPSRead the original story w/Photo

    Monday Aug 8 | AmericanBankingNews.com

    Shares of Dynavax Technologies Corp. have been given an average broker rating score of 2.00 from the four analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

    Comment?

  19. Looking At Dynavax Technologies Corporation (DVAX)'s Upcoming Hep B CatalystsRead the original story w/Photo

    Monday Aug 8 | Insider Monkey

    ... ad blockers. You can sign up for free by clicking here or you can login if you are already a member. Dynavax Technologies Corporation (NASDAQ: DVAX ) just reported its second quarter financials, and alongside the numbers, gave us an update as to the ...

    Comment?

  20. Mid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q3 ExpectationsRead the original story

    Monday Aug 8 | Benzinga

    ... trading on Monday, healthcare shares fell by 0.63 percent. Meanwhile, top losers in the sector included Dynavax Technologies Corporation (NASDAQ: DVAX ), down 7 percent, and BioScrip Inc (NASDAQ: BIOS ), down 5 percent. The company reported net ...

    Comment?